Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Rivera, Raquel
- dc.contributor.author Vilarrasa, Eva
- dc.contributor.author Ribera, M.
- dc.contributor.author Roe, E.
- dc.contributor.author Kueder-Pajares, T.
- dc.contributor.author Zayas, A.I.
- dc.contributor.author Martínez-Molina, L.
- dc.contributor.author Mataix Díaz, J.
- dc.contributor.author Rodríguez-Nevado, I.M.
- dc.contributor.author Usero-Bárcena, T.
- dc.contributor.author Mano, D. de la
- dc.contributor.author García-Donoso, C.
- dc.contributor.author Olveira, A.
- dc.contributor.author Guinea, G.
- dc.contributor.author Martín Vázquez, Víctor
- dc.contributor.author Ferran Farrés, Marta
- dc.date.accessioned 2021-10-22T07:31:26Z
- dc.date.available 2021-10-22T07:31:26Z
- dc.date.issued 2020
- dc.description.abstract Background: Methotrexate (MTX) is frequently used in the treatment of moderate-to-severe psoriasis, however, there is limited data on health-related quality-of-life (HRQoL), psoriasis clinical outcomes and hepatic fibrosis in MTX-treated patients in routine clinical practice. Objectives: To investigate the impact of moderate-to-severe psoriasis in MTX-treated patients in Spain regarding to HRQoL, psoriasis clinical data and risk of hepatic fibrosis. Methods: Observational, non-interventional, cross-sectional, retrospective, multicentre study, performed in Spain in moderate-to-severe plaque psoriasis patients treated with MTX > 16 weeks prior to inclusion. Results: Despite ongoing treatment, 17.1% of 457 evaluable patients reported moderate-to-extreme impact on HRQoL (DLQI > 5); 21.4% BSA > 5 and 35.2% moderate-to-severe pruritus (VAS ≥ 4). Persistent severe psoriasis (PASI ≥ 10 and/or DLQI ≥ 10) was observed in 10.7%. Hepatic steatosis was identified in 64.1% of patients (HSI ≥ 36) and 37.2% of the patients were at-risk of advanced fibrosis which was associated to the MTX treatment duration. Conclusions: The study identified unmet needs in moderate-to-severe plaque psoriasis patients treated with MTX, revealing a significant proportion of sub-optimally controlled patients in terms of HRQoL and different domains of the disease. This study also found patients at-risk of advanced fibrosis, with evidence suggesting a correlation between longer exposures to MTX and higher risk of advanced fibrosis.
- dc.format.mimetype application/pdf
- dc.identifier.citation Rivera R, Vilarrasa E, Ribera M, Roe E, Kueder-Pajares T, Zayas AI, et al. Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study. J Dermatolog Treat. 2020 Sep 8:1-10. DOI: 10.1080/09546634.2020.1801977
- dc.identifier.doi http://dx.doi.org/10.1080/09546634.2020.1801977
- dc.identifier.issn 0954-6634
- dc.identifier.uri http://hdl.handle.net/10230/48761
- dc.language.iso eng
- dc.publisher Taylor & Francis
- dc.rights © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0
- dc.subject.keyword Spain
- dc.subject.keyword Health-related quality of life
- dc.subject.keyword Hepatic fibrosis
- dc.subject.keyword Hepatic steatosis
- dc.subject.keyword Methotrexate
- dc.subject.keyword Psoriasis
- dc.title Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion